PriceTargets.com logo

Novartis - NVS Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $121.50
  • Forecasted Upside: 17.86%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$103.09 As of 11/20/2024 01:00 AM ET
▼ -0.18 (-0.17%)

This chart shows the closing price for NVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novartis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVS

Analyst Price Target is $121.50
▲ +17.86% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $121.50, with a high forecast of $130.00 and a low forecast of $114.00. The average price target represents a 17.86% upside from the last price of $103.09.

This chart shows the closing price for NVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 9 contributing investment analysts is to reduce stock in Novartis. This rating has held steady since August 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 2 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024Erste Group BankReiterated RatingBuy ➝ Hold
10/30/2024BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$118.00 ➝ $120.00
9/11/2024Bank of AmericaDowngradeBuy ➝ Neutral$135.00 ➝ $130.00
9/5/2024The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$119.00 ➝ $121.00
9/3/2024Jefferies Financial GroupDowngradeBuy ➝ Hold
7/19/2024Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Hold
7/2/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$121.00 ➝ $122.50
6/24/2024BarclaysUpgradeStrong Sell
5/30/2024The Goldman Sachs GroupInitiated CoverageBuy$120.00
4/24/2024BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$114.00 ➝ $116.00
2/23/2024BMO Capital MarketsInitiated CoverageMarket Perform$114.00
1/23/2024Morgan StanleyInitiated CoverageEqual Weight$114.00
12/18/2023HSBCDowngradeBuy ➝ Hold
9/25/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight
7/14/2023HSBCInitiated CoverageBuy
4/26/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
4/19/2023BTIG ResearchBoost Target$75.00 ➝ $85.00
3/27/2023Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold
1/26/2023CitigroupDowngradeBuy ➝ Neutral
1/6/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight
1/3/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
12/14/2022UBS GroupBoost TargetNeutral ➝ NeutralCHF 82 ➝ CHF 84
12/5/2022Stifel NicolausUpgradeHold ➝ Buy
10/26/2022JPMorgan Chase & Co.Lower TargetUnderweight ➝ UnderweightCHF 81 ➝ CHF 78
10/14/2022BarclaysLower TargetCHF 85 ➝ CHF 75
10/7/2022Deutsche Bank AktiengesellschaftLower TargetSell ➝ SellCHF 75 ➝ CHF 70
9/29/2022Oddo BhfDowngradeOutperform ➝ NeutralCHF 88
9/15/2022Credit Suisse GroupDowngradeNeutral ➝ Underperform
9/14/2022Berenberg BankDowngradeBuy ➝ Hold
9/8/2022Morgan StanleyLower TargetCHF 97 ➝ CHF 88
9/7/2022Kepler Capital MarketsUpgradeHold ➝ BuyCHF 90
7/20/2022JPMorgan Chase & Co.Boost TargetUnderweight ➝ UnderweightCHF 80 ➝ CHF 81
6/29/2022Deutsche Bank AktiengesellschaftLower TargetCHF 80 ➝ CHF 75
6/3/2022OppenheimerDowngradeOutperform ➝ Market Perform
5/9/2022Wolfe ResearchDowngradeOutperform ➝ Market Perform
5/6/2022Morgan StanleyBoost TargetCHF 90 ➝ CHF 94
4/28/2022Credit Suisse GroupBoost TargetCHF 85 ➝ CHF 88
4/27/2022UBS GroupBoost TargetNeutral ➝ NeutralCHF 85 ➝ CHF 88
4/14/2022BarclaysBoost TargetCHF 80 ➝ CHF 85
4/8/2022UBS GroupBoost TargetCHF 84 ➝ CHF 85
2/28/2022Stifel NicolausInitiated CoverageHold
2/3/2022Societe GeneraleLower TargetCHF 107 ➝ CHF 105
1/10/2022CitigroupInitiated CoverageBuy
12/14/2021Redburn PartnersDowngradeBuy ➝ Neutral
12/6/2021Exane BNP ParibasDowngradeOutperform ➝ NeutralCHF 85
12/6/2021BNP ParibasDowngradeOutperform ➝ Neutral
12/3/2021Bryan, Garnier & CoReiterated RatingBuy ➝ Neutral$115.00 ➝ $85.00
11/5/2021UBS GroupDowngradeBuy ➝ Neutral
10/27/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
10/12/2021Berenberg BankReiterated RatingBuy
10/8/2021UBS GroupReiterated RatingBuy
9/20/2021Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
7/28/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
7/22/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
5/11/2021Morgan StanleyReiterated RatingOverweight
4/28/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
4/28/2021Oddo BhfUpgradeNeutral ➝ Outperform
4/19/2021UBS GroupReiterated RatingBuy
3/23/2021Societe GeneraleReiterated RatingBuy
3/22/2021Sanford C. BernsteinInitiated CoverageMarket Perform
3/16/2021ArgusReiterated RatingBuy ➝ Hold
3/10/2021ArgusDowngradeBuy ➝ Hold
2/2/2021Morgan StanleyReiterated RatingOverweight
2/1/2021CowenDowngradeOutperform ➝ Market Perform$110.00 ➝ $105.00
1/22/2021BarclaysReiterated RatingUnderweight
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy
1/8/2021Morgan StanleyReiterated RatingOverweight
12/3/2020ArgusBoost Target$100.00 ➝ $112.00
11/25/2020UBS GroupReiterated RatingBuy
11/10/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
9/29/2020Berenberg BankInitiated CoverageBuy
9/23/2020Oddo BhfDowngradeBuy ➝ Neutral
9/10/2020UBS GroupUpgradeNeutral ➝ Buy
9/1/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
8/12/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
7/28/2020Morgan StanleyReiterated RatingEqual Weight
6/15/2020CitigroupUpgradeNeutral ➝ Buy
5/11/2020UBS GroupReiterated RatingNeutral
4/29/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
4/29/2020BarclaysReiterated RatingUnderweight
4/23/2020Morgan StanleyReiterated RatingEqual Weight
4/3/2020The Goldman Sachs GroupReiterated RatingBuy$116.00
3/10/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight
2/25/2020GuggenheimDowngradeBuy ➝ Neutral
2/17/2020CitigroupDowngradeBuy ➝ Neutral
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 29 very positive mentions
  • 31 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Mentions as of
4/25/2024
  • 23 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 26 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 28 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/24/2024
  • 21 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 32 very positive mentions
  • 16 positive mentions
  • 6 negative mentions
  • 5 very negative mentions
Mentions as of
9/22/2024
  • 31 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 38 very positive mentions
  • 45 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 38 very positive mentions
  • 45 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Novartis logo
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $103.09
Low: $102.46
High: $103.19

50 Day Range

MA: $112.34
Low: $103.06
High: $117.18

52 Week Range

Now: $103.09
Low: $92.35
High: $120.92

Volume

1,059,764 shs

Average Volume

1,388,621 shs

Market Capitalization

$210.72 billion

P/E Ratio

11.97

Dividend Yield

2.35%

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Novartis?

The following sell-side analysts have issued stock ratings on Novartis in the last twelve months: Bank of America Co., Barclays PLC, BMO Capital Markets, Deutsche Bank Aktiengesellschaft, Erste Group Bank AG, HSBC Holdings plc, Jefferies Financial Group Inc., Morgan Stanley, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for NVS.

What is the current price target for Novartis?

0 Wall Street analysts have set twelve-month price targets for Novartis in the last year. Their average twelve-month price target is $121.50, suggesting a possible upside of 17.9%. Bank of America Co. has the highest price target set, predicting NVS will reach $130.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $114.00 for Novartis in the next year.
View the latest price targets for NVS.

What is the current consensus analyst rating for Novartis?

Novartis currently has 1 sell rating and 8 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for NVS.

What other companies compete with Novartis?

Other companies that are similar to Novartis include Novo Nordisk A/S, AstraZeneca, Sanofi, GSK and Takeda Pharmaceutical. Learn More about companies similar to Novartis.

How do I contact Novartis' investor relations team?

Novartis' physical mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company's listed phone number is (161) 324-1111 and its investor relations email address is [email protected]. The official website for Novartis is www.novartis.com. Learn More about contacing Novartis investor relations.